Psychometric Validation of the QLQ-NMIBC24 in Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Patient-reported outcomes following UGN-102 treatment in low-grade intermediate-risk non-muscle invasive bladder cancer: An analysis of three clinical trials

Pharmacokinetics of UGN-101, a Mitomycin-Containing Reverse Thermal Gel Instilled via Retrograde Catheter for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma 

Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma With UGN-101, a Mitomycin Reverse Thermal Gel

Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report

Thermo Reversible Hydrogel Based Delivery of Mitomycin C (UGN-101) for Treatment of Upper Tract Urothelial Carcinoma (UTUC)

Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel (OLYMPUS): An Open-Label, Single-Arm, Phase 3 Trial 

Durability of Response of UGN-101: Longitudinal Follow Up of Multicenter Study

First Analysis of the Safety and Efficacy of UGN-101 in the Treatment of Ureteral Tumors 

The Ablative Effect of Mitomycin Reverse Thermal Gel: Expanding the Role for Nephron Preservation Therapy in Low Grade Upper Tract Urothelial Carcinoma 

Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes

Mitomycin Gel (UGN-101) as a Kidney-Sparing Treatment for Upper Tract Urothelial Carcinoma in Patients With Imperative Indications and High-Grade Disease 

Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma

Early Experience With UGN-101 for the Treatment of Upper Tract Urothelial Cancer – A Multicenter Evaluation of Practice Patterns and Outcomes

Antegrade Administration of Mitomycin Gel for Upper Tract Urothelial Carcinoma via Percutaneous Nephrostomy Tube: A Multi-Institutional Retrospective Cohort Study 

Antegrade Instillation of UGN-101 (Mitomycin for Pyelocalyceal Solution) for Low-Grade Upper Tract Urothelial Carcinoma: Initial Clinical Experience 

Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With UGN-102: Outcomes From the 5-Year Long-Term Extension Study of the Single-Arm, Phase 2b Optima II Study

Pharmacokinetics of UGN‑102, an Investigational Mitomycin‑Containing Reverse Thermal Gel for the Treatment of Non-Muscle Invasive Bladder Cancer

Review of UGN-102: A Reverse Thermal Gel Containing Mitomycin for the Treatment of Recurrent, Low-Grade, Intermediate-Risk Non–Muscle-Invasive Bladder Cancer

Perceived Impact on Patient Routines/Responsibilities for Surgery and a Nonsurgical Primary Treatment Option in Recurrent Low-Grade Intermediate-Risk Nonmuscle‐Invasive Bladder Cancer: Findings From the ENVISION Phase 3 Trial

Advancements in Hydrogel-Based Therapies as Non-Surgical Alternatives for Urothelial Carcinoma: Ongoing Research and New Insights 

Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION)

Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS)

Minimal Patient-Reported Side Effects for a Chemoablative Gel (UGN-102) Used as Frontline Treatment in Adults With Nonmuscle-Invasive Bladder Cancer 

Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial 

Home Instillation of UGN-102 for Primary Chemoablation of Recurrent, Low-Grade, Intermediate-Risk Non–Muscle-Invasive Bladder Cancer: A Single-Arm, Open-Label, Phase 3b Trial